about
Persistence and compliance with medication management in the treatment of overactive bladderTranslational Research and Functional Changes in Voiding Function in Older AdultsClinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladderA healthy bladder: a consensus statementEstimating EQ-5D and OAB-5D health state utilities for patients with overactive bladderTreatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidenceCost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.Correlation between overactive bladder symptom score and neuropsychological parameters in Alzheimer's disease patients with lower urinary tract symptom.Overactive bladder in the vulnerable elderlyEfficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ERThe influence of an overactive bladder on falling: a study of females aged 40 and older in the communityIncreased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapyCost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands.The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care.Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in CanadaOveractive bladder, differential diagnosis, and clinical utility of fesoterodineComparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.Overactive bladder symptom severity is associated with falls in community-dwelling adults: LOHAS study.Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment.Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experienceSocial, economic, and health utility considerations in the treatment of overactive bladder.Update on the management of overactive bladder: patient considerations and adherencePractical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence.Tolterodine extended release is well tolerated in older subjectsFesoterodine for the treatment of urinary incontinence and overactive bladder.Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns AnalyzerEfficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder.Overactive Bladder Is Strongly Associated With Frailty in Older Individuals.Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK.Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?The Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium: A Transdisciplinary Approach Toward Promoting Bladder Health and Preventing Lower Urinary Tract Symptoms in Women Across the Life Course.Primary care management of overactive bladder symptoms: evaluation and treatment.
P2860
Q26765014-DB9746EE-EE4B-405E-8F94-AC0DA4C8948AQ26782134-35009AC7-A903-4CBC-ABCA-1AE6A3A00573Q26824182-C078D3FE-9730-4576-9A7E-91030BA95A76Q26863299-D34F5C3C-734F-419E-8A8A-61E0C640C947Q27497430-8E7DE172-1B2A-4F35-9755-4BF00CA1785CQ30906698-0AB5EBFE-F96B-49D7-900C-E531860668D0Q31013378-3A66637E-51F8-4E01-AAD5-ED26A1600307Q33692634-66C4D70D-A4BA-4162-91D7-5616D2A3FE9EQ34351806-369EB334-A14E-48CB-8D4A-7EE3F0A74903Q34693256-0309A3D2-42F3-4CCA-8821-9BDC7869FCF5Q34758293-7C6B1DE8-D1FF-48BE-9BAF-10DC932933F6Q35009629-1A4DC50C-5EC6-4326-967D-3CC6EF48831CQ35794880-A9ABEF7F-AFE6-40FD-83E0-9E5D9E7DC083Q36089975-AE68DFFA-CEB0-4C56-9153-4C3EAF003DD0Q36223634-AF904DC3-BAD7-461E-BCE8-8E2D0C776F7FQ36326096-5FE595F0-8CE5-4C6C-ADF2-86E5ACEC0C53Q36429651-77385D81-CCAA-4CC6-AAA6-F16C09AF481CQ36625281-244643C8-77F8-4F14-A68E-A92C4D917CA7Q36821714-B3F7E68D-456F-4E31-A0CE-209C84D9012CQ36855832-A46ACF80-77C4-4B22-8304-EA83D87787CEQ37197554-317D652E-4C4D-4606-B13F-81A1D144E6FBQ37283547-1306DA79-2573-4E04-AA43-417814966556Q37283704-93B080CB-1A89-4FE5-8C9F-97F35F6341A5Q37325841-9770ABC9-B307-4C6D-AEE8-1069C3DE69DDQ37332901-BAE5A86F-46A4-43BD-B989-148649AAB5B9Q37429813-CF17337E-0203-4A0C-928F-1AD53E6F6EC4Q37441427-E3CAF891-8E6E-4B51-8FEE-E4684E1CC8A4Q37672836-B76C45EC-780D-4351-AEBB-D1A08FD7D4AFQ38786937-D6600376-90AC-45DD-B66C-D2EC06EA395CQ46638388-59A9EE0F-592B-41B3-93D8-0E1210F16F21Q47117943-C581DFAB-2D6B-48A1-A4AA-C0B85FF401C4Q52596571-4DA00DAB-5894-4E3B-91A6-D3A3732C42BCQ55417530-118C0D5E-4698-4AB8-A57C-04AFB6C2ABB5
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Comorbidities associated with overactive bladder.
@ast
Comorbidities associated with overactive bladder.
@en
Comorbidities associated with overactive bladder.
@nl
type
label
Comorbidities associated with overactive bladder.
@ast
Comorbidities associated with overactive bladder.
@en
Comorbidities associated with overactive bladder.
@nl
prefLabel
Comorbidities associated with overactive bladder.
@ast
Comorbidities associated with overactive bladder.
@en
Comorbidities associated with overactive bladder.
@nl
P2093
P1476
Comorbidities associated with overactive bladder.
@en
P2093
Chokroverty S
P304
P433
P577
2000-07-01T00:00:00Z